Drug Delivery Devices Market Report 2025

The drug delivery devices market size has grown strongly in recent years. It will grow from $91.03 billion in 2024 to $96.73 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to rapid growth in elderly population, growth in the number of healthcare facilities, economic growth in the emerging markets and increased healthcare expenditure.

The drug delivery devices market size is expected to see strong growth in the next few years. It will grow to $124.82 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to increase in prevalence of chronic diseases, increasing demand from injectables, increasing demand for drug delivery devices and sudden emergence of severe infections. Major trends in the forecast period include investing in microneedle drug technology for drug delivery, research and development of self-injectable drug delivery devices, focusing on mergers and acquisitions and investing in wearable drug delivery devices.

The increasing prevalence of chronic diseases such as cardiovascular diseases, diabetes, cancer, and other conditions is expected to propel the drug delivery devices market. For example, in January 2023, according to the National Library of Medicine, the number of individuals in the United States aged 50 and older with at least one chronic condition is projected to increase by 99.5%, reaching 142.66 million by 2050 from 71.522 million in 2020. Various routes of drug administration exist, and the choice depends on three factors, the desired effect, the type of disease, and the product type. The pharmaceutical industry is currently emphasizing the development of new drug delivery systems, driven by increasing R&D efforts worldwide due to the rising prevalence of chronic diseases. Many pharmaceutical companies are concentrating on multiple drug delivery technologies to enhance advantages and improve outcomes for their products. Therefore, the growing prevalence of chronic diseases is leading to increased consumption of therapeutic drugs and therapies, acting as a driver for the drug delivery devices market's growth.

The growth of the drug delivery devices market is expected to be driven by increasing healthcare spending in the future. Healthcare spending encompasses the total financial resources allocated to health services and goods, which includes expenses related to hospitals, physicians, nursing care, prescription medications, and public health initiatives. This rise in healthcare spending is attributed to factors such as an aging population, a growing prevalence of chronic diseases, advancements in medical technology, and escalating costs associated with healthcare services and prescription drugs. Greater healthcare expenditure facilitates the development of drug delivery devices by providing additional funding for research, innovation, and the implementation of advanced technologies that enhance treatment efficacy and improve patient outcomes. For example, in May 2024, the Office for National Statistics, a UK government department, reported that healthcare expenditure in the UK reached approximately $379 billion (£292 billion) in 2023. This represented a nominal increase of 5.6% compared to 2022, a significant rise from the 0.9% growth noted in the previous year. Consequently, the increasing healthcare spending is driving the growth of the drug delivery devices market.

Major companies in the drug delivery device market are concentrating on developing innovative solutions, such as autoinjectors with fully integrated connectivity, to secure a competitive advantage. Autoinjectors are medical devices designed for the self-administration of a pre-measured dose of medication. For example, in May 2022, Jabil Healthcare, a U.S.-based provider of healthcare manufacturing solutions, introduced the Qfinity autoinjector platform, which is a reusable drug delivery device. The Qfinity platform is notable for being a simple, reusable, and modular solution for subcutaneous self-administration of drugs, offering a cost-effective alternative to competitors while supporting sustainable drug delivery practices within the pharmaceutical industry. Its versatile design accommodates various drug volumes and viscosities and features a patient-centric form factor, achieving up to 65% lower cost per injection compared to leading disposable autoinjectors. The robust Qfinity device is capable of supporting over 100 injections and utilizes 1 mL or 2.25 mL pre-filled disposable cassettes. Furthermore, its reduced component and material consumption leads to an estimated 65% reduction in cost per injection, a 60% smaller carbon footprint, a 50% reduction in manufacturing footprint, and a 70% decrease in capital expenditure (CAPEX).

Microneedle (MN) technology is recognized for its efficiency and versatility in the medical device landscape, boasting attributes such as painless penetration, cost-effectiveness, high therapeutic efficacy, and relative safety. Key players in the global microneedle drug delivery system market include 3M, Vetter Pharma International GmbH, Nano Biosciences LLC, Nano Pass, and others. Microneedles are crafted using biodegradable polymers that encapsulate drugs or vaccines. Upon dissolution in the skin, the microneedles release the drug. This innovative delivery method facilitates the passage of a diverse range of molecules through the skin barrier, allowing transdermal delivery for various clinical applications, including diabetes, severe osteoporosis, and influenza vaccination.

In March 2022, Sandoz Group AG, a Switzerland-based pharmaceutical company, acquired Coalesce Product Development Limited for an undisclosed amount. This acquisition aligns with Sandoz's strategic goal of expanding its current respiratory medication portfolio and enhancing patient access to advanced treatments. Coalesce Product Development Limited, based in the UK, specializes in the manufacturing of respiratory medical and medication delivery devices.

Major companies operating in the drug delivery devices market include Becton, Dickinson and Company, Baxter International, B. Braun Melsungen AG, Catalent, 3M Company, West Pharmaceutical Services, Inc., Gerresheimer AG, Smiths Medical, Boehringer Ingelheim, SMC Ltd., Elcam Medical, Eli Lilly and Company, Injex, Novartis AG, Novo Nordisk A/S, Pfizer Inc, Sanofi Sa, Schott AG, Terumo Corporation, Teva Pharmaceuticals, Ypsomed Holding AG, F. Hoffmann-La Roche AG, GlaxoSmithKline, AstraZeneca, Congenica Ltd., UCB, Alkermes, Aptalis Pharma, Inc., Johnson & Johnson, Nektar Therapeutics, SkyePharma PLC, Pharmasyntez, NEARMEDIC PLUS LLC, Copernicus, Medtronic, Philips, Siemens, Stryker, GE Healthcare, Teleflex Medical, Gilero, Kedalion Therapeutics, MediPrint Ophthalmics, Nemera, Pendant Biosciences, Battelle Medical Devices, Merck & Co. Inc., Antares Pharma, Abbot, Allergan, Bilim Pharmaceuticals, H&T Presspart, Hovione Technology, Sorrel Medical, Syqe Medical, Julphar, ResMed Inc, Covidien plc.

North America was the largest region in the drug delivery devices market in 2024. Asia-Pacific was the second-largest region in the global drug delivery devices market. The regions covered in the drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drug delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

Drug delivery devices are designed to administer specific drugs to targeted areas of the body for disease treatment. These devices find application in various patient care environments, including hospitals, diagnostic centers, clinics, and home care settings.

The primary routes of drug administration through these devices encompass oral drug delivery, injectable drug delivery, topical drug delivery, ocular drug delivery, pulmonary drug delivery, nasal drug delivery, transmucosal drug delivery, and implantable drug delivery. Oral drug delivery involves the administration of a tablet or capsule into the alimentary canal of a human being. Patient care settings where these devices are utilized include hospitals, diagnostic centers, ambulatory surgery centers/clinics, home care settings, and others. The diverse applications of these drug delivery devices span across areas such as cancer, infectious diseases, respiratory diseases, diabetes, cardiovascular diseases, autoimmune diseases, central nervous system disorders, and more.

The drug delivery devices market research report is one of a series of new reports that provides drug delivery devices market statistics, including drug delivery devices industry global market size, regional shares, competitors with a drug delivery devices market share, detailed drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the drug delivery devices industry. This drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The drug delivery devices market consists of sales of instruments such as smart pills, inhalers and nebulizers, drug-eluting stents, safety syringes, and transdermal patches. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.